3 top healthcare shares with enormous potential

I think that one of the areas of the market with the most positive long-term outlook is the healthcare sector.

Technological advances, growing and ageing populations, and increased chronic disease burden are just a few factors that are expected to lead to solid growth in the sector over the long-term.

In light of this, I think having a little exposure to the healthcare sector is a great thing for a portfolio.

Here are three ways you could do it:

CSL Limited (ASX: CSL)

If you only have one healthcare share in your portfolio, make it CSL. I think that this biotherapeutics company’s half-year result last month showed investors why it is regarded as one of the highest quality companies in Australia. Furthermore, I believe that result demonstrated the significant potential of its fledgling Seqirus influenza business. Ultimately, I feel the emergence of Seqirus should support the growth being exhibited by its core business, leading to solid profit growth over the coming years.

Pro Medicus Limited (ASX: PME)

I think that Pro Medicus’ Visage 7 technology has enormous potential. The technology allows radiologists and physicians to visually assess a patient’s complete imaging history, along with the flexibility to access, finely choreograph, and immediately display any combination of imaging components. Unsurprisingly, it has been attracting more and more users. One of which, Yale New Haven Health, signed a seven-year deal which will see Visage 7 implemented across all its radiology departments.

ResMed Inc. (CHESS) (ASX: RMD)

This global healthcare company specialises in the treatment of sleep apnoea and other chronic respiratory diseases. I’ve been very impressed at its consistently strong growth on both the top and bottom line over the last few years. One such example was that it recently reported non-GAAP income of US$143.8 million in the first-half of FY 2018, up a sizeable 39% on the prior corresponding period. I expect more of the same in the future thanks to its strong market-position, quality products, and growing cloud-based software offering.

Here are three more shares that I think have huge potential in the future as well. I would suggest investors snap them up before they take off.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended PRO Medicus Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.